Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Allen C, Barber RM, et al; Global Burden of Disease Cancer C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–548. doi:10.1001/jamaoncol.2016.568827918777
   PubMed Web of Science ®Google Scholar
• Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527. doi:10.1016/S0140-6736(16)31594-X28017406
   PubMed Web of Science ®Google Scholar
• Popat R, Oakervee H, Williams C, et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol. 2009;144(6):887–894. doi:10.1111/j.1365-2141.2008.07572.x19183191
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320. doi:10.1056/NEJMoa161175028379796
   PubMed Web of Science ®Google Scholar
• Minarik J, Pavlicek P, Pour L, et al. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One. 2015;10(4):e0123866. doi:10.1371/journal.pone.012386625875484
   PubMed Web of Science ®Google Scholar
• Mu S-D, Ai L-S, Qin Y, Hu Y. Subcutaneous versus intravenous bortezomib administration for multiple myeloma patients: a meta-analysis. Curr Med Sci. 2018;38(1):43–50. doi:10.1007/s11596-018-1844-y30074150
   PubMed Web of Science ®Google Scholar
• Rubin GJ, Amlôt R, Page L, Wessely S. Public perceptions, anxiety, and behaviour change in relation to the swine flu outbreak: cross sectional telephone survey. Bmj. 2009;339:b2535. doi:10.1136/bmj.b265119622551
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.8721797
   PubMedGoogle Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.7786990
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–634.9310563
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440. doi:10.1016/S1470-2045(11)70081-X21507715
   PubMed Web of Science ®Google Scholar
• Moreau P, Coiteux V, Hulin C, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica. 2008;93(12):1908–1911. doi:10.3324/haematol.1328518768528
   PubMed Web of Science ®Google Scholar
• Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925–1928. doi:10.3324/haematol.2012.06779322689676
   PubMed Web of Science ®Google Scholar
• Merz M, Salwender H, Haenel M, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100(7):964–969. doi:10.3324/haematol.2015.12434725840597
   PubMed Web of Science ®Google Scholar
• Xu Y, Deng S, Mao X, et al. Tolerance, kinetics, and depth of response for subcutaneous versus intravenous administration of bortezomib combination in Chinese patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(6):422–430. doi:10.1016/j.clml.2018.03.00629625927
   PubMed Web of Science ®Google Scholar
• Koh Y, Lee SY, Kim I, et al. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemother Pharmacol. 2014;74(3):653–657. doi:10.1007/s00280-014-2555-025096796
   PubMed Web of Science ®Google Scholar
• Lamm W, Drach-Schauer B, Eder S, Drach J. Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology. 2013;85(4):223–227. doi:10.1159/00035519724080991
   PubMed Web of Science ®Google Scholar
• Wu S, Zheng C, Chen S, et al. Subcutaneous administration of bortezomib in combination with thalidomide and dexamethasone for treatment of newly diagnosed multiple myeloma patients. Biomed Res Int. 2015;2015:927105. doi:10.1155/2015/92710526425561
   PubMed Web of Science ®Google Scholar
• St-Pierre Y, Sidana S, Narkhede M, et al. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS One. 2017;12(3):e0172996. doi:10.1371/journal.pone.017299628278302
   PubMed Web of Science ®Google Scholar
• Liu H, Fu CC, Xue SL, et al. Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novo patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2013;34(10):868–872. doi:10.3760/cma.j.issn.0253-2727.2013.10.00924171961
   PubMedGoogle Scholar
• Wang YS, Ding SH, Wu F, Wang ZT, Wang QS. Safety and efficacy of subcutaneous administration of bortezomib in the treatment of multiple myeloma. Sichuan da xue xue bao Yi xue ban. 2014;45(3):529–532.24941833
   PubMedGoogle Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946–2955. doi:10.1200/JCO.2011.39.682022802322
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143(4):537–540. doi:10.1111/j.1365-2141.2008.07359.x18783399
   PubMed Web of Science ®Google Scholar
• Dispenzieri A. Bortezomib for myeloma – much ado about something. N Engl J Med. 2005;352(24):2546–2548. doi:10.1056/NEJMe05805915958811
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137(5):429–435. doi:10.1111/j.1365-2141.2007.06585.x17451408
   PubMed Web of Science ®Google Scholar
• Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51(12):823–829. doi:10.1007/s40262-012-0010-023018466
   PubMed Web of Science ®Google Scholar
• Barbee MS, Harvey RD, Lonial S, et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother. 2013;47(9):1136–1142. doi:10.1177/106002801350312224259728
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009;27(21):3518–3525. doi:10.1200/JCO.2008.18.308719528374
   PubMed Web of Science ®Google Scholar
• Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777–3784. doi:10.1182/blood-2005-03-117316099887
   PubMed Web of Science ®Google Scholar
• Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J Am Acad Dermatol. 2006;55(5):897–900. doi:10.1016/j.jaad.2006.06.03017052502
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113–3120. doi:10.1200/JCO.2005.04.777916754936
   PubMed Web of Science ®Google Scholar
• Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110(5):1042–1049. doi:10.1002/cncr.2292117654660
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593–1599. doi:10.1182/blood-2008-04-14938518574024
   PubMed Web of Science ®Google Scholar